Few & Far Between: How Biotech Gets Built

"If  you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how  de novo proteins can be used to reprogram immune cells . Tune in today!

"It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they are not destroyed during nebulization." - Dr. Carsten Rudolph, CEO and Managing Director at Ethris Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Dr. Carsten Rudolph, as they discuss the current st...

"W e don't endeavor to make elite athletes better. We endeavor to make society healthier." - Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Jonathan Scheiman, as they discuss microbiome solutions for next generation health and longevity. Tune in today!

"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than specialized knowledge." - Isaac Stoner, Co-founder and CEO at Octagon Therapeutics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Isaac Stoner, as they discuss immunology, how to build a company, and financin...

“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really hope that as we scale up and generate more data, we can actually move to newly diagnosed patients.” - Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical Welcome to the latest episode of Bior...

"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help and a company that can help." - Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Craig Serra, as they discuss improving...

"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the UK's first NIHR Research Translational Professor of Oncology, Professor of Biomedical Sciences, Anglia Ruskin University, Cambridge. Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and g...

"Technologies have changed enormously in terms of how we can basically procure , preserve, and then interrogate a tumor specimen...like effectively in real time, like a living cancer specimen." - Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Associate Physician of Hematology and Oncology at Ma...

"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to really accelerate medicine's development." - Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School. Welcome to the February episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Ole Isacson, P...

"T he history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will Greene, Prader-Willi syndrome patient advocate and Healthcare Engagement Lead at Roche Welcome to Biorasi's first Few & Far Between episode of 2024! Join host Chris O'Brien and guest Will Greene, Prader-Willi syndrome (PWS) patient advocate and Healthcare...